Physician profile
Daniel Breeyear
NPI 1922620178
$148,892.60
in general payments reported to CMS, 2019-2025
21 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,330 · 2022: $2,332 · 2023: $23K · 2024: $25K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Consulting Fee: $33K · Honoraria: $30K · Travel and Lodging: $30K · Food and Beverage: $14K · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,760.00 |
| Consulting Fee | $33,062.50 |
| Honoraria | $29,990.00 |
| Travel and Lodging | $29,677.65 |
| Food and Beverage | $13,674.59 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $83,334.28 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57,074.90 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,567.12 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $1,190.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,186.60 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $731.50 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $603.62 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $596.53 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $507.63 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $453.80 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $434.44 | 2022-2024 | Azstarys |
| Novo Nordisk INC | $370.57 | 2022-2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $189.71 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $141.49 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $137.00 | 2021-2024 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $128.45 | 2022-2025 | Sublocade |
| Lilly USA, LLC | $74.53 | 2024-2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $70.87 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $44.77 | 2022-2023 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $31.57 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $22.23 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Breeyear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.